Cargando…
Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available ni...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960313/ https://www.ncbi.nlm.nih.gov/pubmed/35359396 http://dx.doi.org/10.3389/fonc.2022.853211 |
_version_ | 1784677365418295296 |
---|---|
author | Wei, Qiang Chen, Dong-Sheng Liu, Yuan-Hua |
author_facet | Wei, Qiang Chen, Dong-Sheng Liu, Yuan-Hua |
author_sort | Wei, Qiang |
collection | PubMed |
description | Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available niraparib treatment-related adverse events, gastrointestinal disorders and hematological toxicities were most commonly reported with manageable safety profile. Herein, we first describe a severe and never-reported pulmonary embolism (PE) associated with the use of niraparib in a patient with BRCA mutation advanced high-grade serous ovarian cancer and received anticoagulant therapy after PE. There have been no reports of PE caused by the use of niraparib in patients with advanced high-grade serous ovarian cancer; knowledge of the occurrence of PE after the use of niraparib may assist other clinicians in managing this rare but potentially serious toxic effect. |
format | Online Article Text |
id | pubmed-8960313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89603132022-03-30 Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer Wei, Qiang Chen, Dong-Sheng Liu, Yuan-Hua Front Oncol Oncology Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available niraparib treatment-related adverse events, gastrointestinal disorders and hematological toxicities were most commonly reported with manageable safety profile. Herein, we first describe a severe and never-reported pulmonary embolism (PE) associated with the use of niraparib in a patient with BRCA mutation advanced high-grade serous ovarian cancer and received anticoagulant therapy after PE. There have been no reports of PE caused by the use of niraparib in patients with advanced high-grade serous ovarian cancer; knowledge of the occurrence of PE after the use of niraparib may assist other clinicians in managing this rare but potentially serious toxic effect. Frontiers Media S.A. 2022-03-10 /pmc/articles/PMC8960313/ /pubmed/35359396 http://dx.doi.org/10.3389/fonc.2022.853211 Text en Copyright © 2022 Wei, Chen and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wei, Qiang Chen, Dong-Sheng Liu, Yuan-Hua Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer |
title | Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer |
title_full | Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer |
title_fullStr | Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer |
title_full_unstemmed | Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer |
title_short | Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer |
title_sort | case report: niraparib-related pulmonary embolism during the treatment of brca mutant advanced ovarian cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960313/ https://www.ncbi.nlm.nih.gov/pubmed/35359396 http://dx.doi.org/10.3389/fonc.2022.853211 |
work_keys_str_mv | AT weiqiang casereportniraparibrelatedpulmonaryembolismduringthetreatmentofbrcamutantadvancedovariancancer AT chendongsheng casereportniraparibrelatedpulmonaryembolismduringthetreatmentofbrcamutantadvancedovariancancer AT liuyuanhua casereportniraparibrelatedpulmonaryembolismduringthetreatmentofbrcamutantadvancedovariancancer |